EUCTR2018-004145-16-ES进行中（未招募）1 期
A 12-weeks, multicentre, randomized, double-blind, placebo-controlled, exploratory, pilot study to evaluate the safety and efficacy of safinamide 200 mg once daily, as add-on therapy, in patients with possible or probable parkinsonian variant of multiple system atrophy. - Safinamide for Multiple System Atrophy
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- Zambon SpA
- 入组人数
- 49
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Participants are eligible to be included in the study only if all of the following criteria apply:
- •1. Participant must be 30 to 80 years of age inclusive, at the time of signing the informed consent.
- •Type of Participant and Disease Characteristics
- •2. Participants who are diagnosed (with MRI confirmation) with possible or probable parkinsonian variant of Multiple System Atrophy less than 2 years ago.
- •3. Participants with an anticipated survival of at least 3 years in the opinion of the investigator.
- •4. Male or female
- •A female participant is eligible to participate if she is not pregnant, not breastfeeding, and at least one of the following conditions applies (see Appendix 4):
- •i. Not a woman of childbearing potential (WOCBP)
- •ii. A WOCBP who agrees to follow the contraceptive guidance during the treatment period and for at least 30 days after the last dose of study intervention.
- •Informed Consent
- •5. Capable of giving signed informed consent as described in Appendix 1 which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 24
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 24
排除标准
- •Participants are excluded from the study if any of the following criteria apply:
- •Medical Conditions
- •1. History of neurosurgical procedure, including stereotactic surgery.
- •2. History of Deep Brain Stimulation (DBS)
- •3. History of bipolar disorder, severe depression, schizophrenia or other psychotic disorder.
- •4. History of drug and/or alcohol abuse within 12 months prior to screening as defined by the current edition of the Diagnostic and Statistical Manual of Mental Disorders
- •5. History of dementia (DSM-V criteria)
- •6. Ophthalmologic history including any of the following conditions: albinism, uveitis, retinitis pigmentosa, retinal degeneration, active retinopathy, severe progressive diabetic retinopathy, inherited retinopathy or family history of hereditary retinal disease.
- •7. Active hepatitis B or C
- •8. History of human immunodeficiency virus (HIV) infection
- •9. Subjects not able to swallow oral medications
- •10. Subjects with severe orthostatic symptoms
- •11. Impaired ambulation, i.e. falling more than once per week, bedridden patients or confined to a wheelchair during the whole day.
- •12. Subjects with active malignant neoplasms.
- •13. Movement disorders other than MSA (e.g. Parkinson Disease, dementia with Lewy bodies, essential tremor, progressive supranuclear palsy, pharmacological or post-encephalic parkinsonism).
- •14. Any clinically significant or unstable medical or surgical condition that, in the opinion of the investigator, might preclude safe completion of the study or might affect the results of the study.
- •Prior/Concomitant Therapy
- •15. Not on a stable regime, for at least 4 weeks prior to the randomization (baseline visit), of
- •a. oral levodopa (including controlled release [CR], immediate release [IR] or a combination of CR/IR), with or without benserazide/carbidopa, with or without addition of a catechol O-methyltransferase (COMT) inhibitor
- •b. dopamine agonist, anticholinergic and/or amantadine.
- •Prior/Concurrent Clinical Study Experience
- •16. Patients should not have received treatment with monoamine oxidase inhibitors in the 2 weeks prior to the randomization visit, nor treatment with levodopa infusion, pethidine, opiates, opioids, fluoxetine, fluvoxamine in the 4 weeks prior to the randomization visit.
- •17. Patients should not have received treatment with an oral or depot neuroleptic within 12 weeks prior to the randomization visit.
- •18. Use of any investigational drug within 30 days prior to screening or 5 half-lives, whichever is the longest.
- •Diagnostic assessments
- •19. Montreal Cognitive Assessment (MoCA) = 20
- •20. Laboratory assessments showing moderate or severe hepatic impairment (2x ULN)
- •Other Exclusions
- •21. Allergy/sensitivity or contraindications to the investigational medicinal products (IMPs) or their excipients, anticonvulsants, levodopa or other anti-parkinsonian drugs.
- •22. Any clinically significant condition which, in the opinion of the Investigator, would not be compatible with study participation or represent a risk for patients while in the study.
研究者
相似试验
进行中（未招募）
1 期
A study evaluating the safety and efficacy of safinamide for patients with Multiple System AtrophyParkinsonian variant of Multiple System AtrophyMedDRA version: 21.1Level: PTClassification code 10064060Term: Multiple system atrophySystem Organ Class: 10029205 - Nervous system disordersEUCTR2018-004145-16-ITZAMBON SPA48
已完成
3 期
A 12-week, multicentre, randomised, double-blind, double-dummy, 2-arm parallel group study comparing the efficacy and safety of Foster® 100/6 (beclomethasone dipropionate 100 µg plus formoterol 6 µg/actuation), 2 puffs b.i.d., versus Symbicort® 200/6 (budesonide 200 µg plus formoterol 6 µg/actuation), 2 inhalations b.i.d., on parameters of small airway function in patients with Chronic Obstructive Pulmonary Disease.Lung of smoker10037454chronic bronchitisNL-OMON38416Chiesi Farmaceutici170
进行中（未招募）
不适用
Multicentre, randomized research study to test the safety and efficacy of Foster® compared to Symbicort® on small airway function in patients with COPD (Chronic Obstructive Pulmonary Disease)EUCTR2010-022895-30-NLChiesi Farmaceutici S.p.A.170
进行中（未招募）
1 期
Study of efficacy and safety of CSJ117 in patients with severe uncontrolled asthmaAsthmaEUCTR2019-004905-29-BGovartis Pharma AG625
进行中（未招募）
1 期
Study of efficacy and safety of CSJ117 in patients with severe uncontrolled asthmaAsthmaMedDRA version: 20.0Level: PTClassification code 10003553Term: AsthmaSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2019-004905-29-DEovartis Pharma AG625